Alveolar type 2 progenitor cells (AT2) seem closest to clinical translation, specifying the
evidence that AT2 may satisfactorily control the immune response to decrease lung injury by …

Studies developing and applying organoid technology have greatly increased in volume
and visibility over the past decade. Organoids are three‐dimensional structures that are …

Patients with coronavirus disease 2019 (COVID-19) present a wide range of acute clinical
manifestations affecting the lungs, liver, kidneys, and gut. Angiotensin-converting enzyme 2 …

Lung injury activates specialized adult epithelial progenitors to regenerate the epithelium.
Depending on the extent of injury, both remaining alveolar type II cells (AEC2s) and distal …

Development of organoids and microfluidic on-chip models has enabled studies of organ-
level disease pathophysiologies in vitro. However, current lung-on-a-chip platforms are …

The respiratory epithelium is intimately associated with the pathophysiologies of highly
infectious viral contagions and chronic illnesses such as chronic obstructive pulmonary …

Pulmonary fibrosis (PF) is a chronic and relentlessly progressive interstitial lung disease in
which the accumulation of fibroblasts and extracellular matrix (ECM) induces the destruction …

Protein supplementation therapy using in vitro-transcribed (IVT) mRNA for genetic diseases
contains huge potential as a new class of therapy. From the early ages of synthetic mRNA …

Chronic obstructive pulmonary disease (COPD) represents a worldwide concern with high
morbidity and mortality, and is believed to be associated with accelerated ageing of the lung …

Alveolar macrophage (AM) is a mononuclear phagocyte key to the defense against
respiratory infections. To understand AM's role in airway disease development, we …